TELA Bio Q3 revenue $20.7M (+9% YoY); upsizes credit facility to $70M with Perceptive

TELA Bio, Inc.

2025-Q3 EPS reported -$0.66 vs consensus -$0.20 ▼ miss (-225.1%)

Q3 revenue $20.7M (+9% YoY); net loss $8.6M vs $10.4M year ago; operating loss $7.6M.
Full-year 2025 revenue guidance revised to at least 16% growth over 2024.
Closed $70M credit facility from Perceptive Advisors: $60M initial draw, $10M accordion; interest rate 7.85%+greater of Term SOFR or 4.25%, interest-only to Nov 2030.
Appointed Betty Jo Rocchio and Bill Plovanic to the Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.